Highest-materiality recent filing
Glucotrack raises $2M via 22% OID secured convertible notes and sets 1-for-2 reverse split
Issued $2.56M principal of 8% senior secured convertible notes due 9 months for $2.0M cash, a 22% original issue discount; default rate 18%.
Glucotrack (Lōkahi) advances LT-100, submits protocol; ai² platform flags 45 assets
Completed strategic business combination on July 14, 2026; Glucotrack Technologies now wholly owned subsidiary.
Glucotrack raises $11.6M convertible notes: $4.5M cash, rollover of existing notes
Issued $11,596,172.68 in senior secured convertible notes: $4.5M cash plus $4,545,014.69 rollover; 22% original issue discount.
Glucotrack settles Alto debt dispute with $2M cash and $2M convertible note
Settlement with Alto resolves ~$10.9M asserted debt from Apimeds Pharmaceuticals; Glucotrack and others jointly liable.
Glucotrack's Lokahi acquisition target: $53K cash, $8.1M H1 loss, going concern doubt
Lokahi had $53,186 cash and no revenue as of June 30, 2026; total assets $2.5M vs liabilities $9.2M.
Glucotrack announces 1-for-15 reverse stock split effective Aug 31, 2026
1-for-15 reverse split effective at market open Aug 31, 2026; shares cut from 11,972,157 to ~798,144.
Glucotrack shareholders approve 1:30 reverse split and warrant inducement at 2026 annual meeting
All six director nominees elected; votes for ranged 934,050-961,363; ~1.67M broker non-votes.
Glucotrack raises $5.5M in combined equity and convertible debt financing
$2.0M equity PIPE at $0.75/unit: each unit includes one share (or pre-funded warrant) and a 5-year warrant at $1.50.
Glucotrack subsidiary Lokahi advances LT-100 to single-injection strategy after FDA meeting
Lokahi Therapeutics (GCTK subsidiary) plans to simplify LT-100 from 15 intradermal injections to a single subcutaneous injection per visit.
Glucotrack completes reverse merger with Lokahi; existing holders get 10% floor
Lokahi shareholders receive 90% of fully diluted equity; existing Glucotrack holders get at least 10%.
Glucotrack receives second Nasdaq delisting notice; plans to appeal by May 18
First notice on May 11: non-compliance with minimum bid price of $1.00.
Glucotrack Q1 net loss $4.3M, IDE submitted to FDA for implantable CGM
Net loss $4.3M vs $6.8M YoY; cash $3.9M as of March 31, 2026.
Study in Journal of Diabetes Research shows weighted average MARD of 6.8% across 79 IV glucose tolerance tests in ovine model.
Glucotrack reports FY2025 net loss $19.4M; cash $7.4M; plans IDE filing Q2 2026
Net loss for FY2025 was $19.4M, down from $22.6M in 2024; no product revenue.
Glucotrack to file IDE with FDA for implantable CBGM in Q2 2026, citing positive trial results
Brazil first-in-human study (Dec 2024-Jan 2025) showed MARD 7.7%, 99% data capture, and zero serious adverse events.
Glucotrack receives USPTO approval for three CBGM patents
Three US patents issued by USPTO: US 12,453,494 (Oct 28, 2025), US 12,458,257 and US 12,458,258 (Nov 4, 2025).
Q3 2025 net loss $4.2M ($4.64 per share) vs $5.1M in Q3 2024; nine-month net loss $15.8M.
Special Meeting reconvenes November 7, 2025 at 12 p.m. ET to vote on Equity Purchase Agreement with Sixth Borough Capital Fund LP.
Glucotrack issues $3.6M convertible note at $3M price; ELOC proceeds to repay
Issued $3.6M convertible promissory note for $3M purchase price ($600K OID), no interest, due in 12 months or upon Qualified Financing.
Glucotrack signs up to $20M equity purchase agreement with Sixth Borough Capital Fund
Investor committed to buy up to $20M of common stock over 24 months at company's discretion.
Net loss of $11.6M for H1 2025 vs $7.4M prior year; operating expenses rose $0.9M.
Glucotrack appoints David S. Hirsh, MD as Medical Director, Cardiology
Dr. Hirsh, a cardiac electrophysiologist, joins Glucotrack's clinical advisory team for its CBGM program.
Glucotrack to exhibit CBGM at ADCES; touts progress toward US pilot study
Presenting at ADCES Annual Meeting Aug 8-11, 2025 in Phoenix, AZ; CBGM at Booth #1724.
Glucotrack repurchases ~49,700 Series A warrants, cuts potential dilution
Repurchased over 90% of Series A Warrants on June 30, 2025 for cash on hand in a negotiated transaction.
Glucotrack reports positive final first-in-human CBGM study results with MARD 7.7%
Study met all endpoints; MARD 7.7% across 122 matched pairs, 99% data capture, no serious adverse events.
Glucotrack executes 1-for-60 reverse stock split effective June 13, 2025
Reverse split approved by stockholders on May 22; reduces outstanding shares from 34,047,337 to ~567,456.
1-for-60 reverse stock split approved by shareholders on May 22, 2025, effective at market open on June 16, 2025.
On September 14, 2026, Paul V. Goode notified the Board of Directors of Glucotrack, Inc. (the “Company”) of his resignation from the Board, effective immediately.
On January 27, 2025, James Cardwell informed the Board of Directors (the “Board”) of Glucotrack, Inc. (the “Company”) that he was resigning as Chief Financial Officer of the Company, effective immediately.
In connection with Mr. Cardwell’s resignation, on January 28, 2025, the Board appointed Peter C. Wulff as Chief Financial Officer of the Company.
On August 27, 2024, the Board of Directors of Glucotrack, Inc. (the “Company”) appointed Paul V. Goode, and Mr. John Ballantyne to the Board of Directors (the “Board”) as board members.
On August 27, 2024, the Board of Directors of Glucotrack, Inc. (the “Company”) appointed Paul V. Goode, and Mr. John Ballantyne to the Board of Directors (the “Board”) as board members.
On July 29, 2024, Shimon Rapp and Andrew Sycoff resigned from the board of directors.
On July 29, 2024, Shimon Rapp and Andrew Sycoff resigned from the board of directors.
On June 14, 2024, the Board of Directors of Glucotrack, Inc. (the “Company”) appointed Andrew K. Balo to the Board of Directors as an independent board member.
Effective as of October 6, 2023, Jolie Kahn resigned as Chief Financial Officer of GlucoTrack, Inc. (the “Company”) to pursue other career interests.
On October 11, 2023, the Company appointed James S Cardwell, 63, as Chief Financial Officer of the Company, effective immediately.
On August 25, 2023, the Board of Directors of GlucoTrack, Inc. appointed Erin Carter as a director to serve until her successor is elected and duly qualifies.
In connection with the Company’s previously announced plans to migrate certain aspects of product development to the United States, James P. Thrower PhD, Vice President of Engineering, will be assuming Mr. Shushan’s responsibilities.
Max materiality 1.00 · Median 0.60 · Most common event other_material